started · updated
India launches Biovigilance Programme to enhance medicine and transplant safety
India has launched the ‘Biovigilance Programme of India’ (BvPI) to monitor adverse reactions associated with medicines and biological products used in organ and tissue transplants. The announcement was made by Union Minister of State for Health and Family Welfare Anupriya Patel during the 6th National Pharmacovigilance Week.
In addition to the new biovigilance initiative, the government released the 7th edition of the National Formulary of India (NFI), which includes a digital version. The NFI serves as a guidance document for hospitals regarding the safety monitoring and reporting of medical device-related adverse events. The Minister also noted the launch of the ADR-PvPI 2.0 mobile app for iOS users.
Patel highlighted that India has significantly improved its global standing in patient safety, moving from 123rd place between 2009–2014 to 8th globally in contributions to the World Health Organization (WHO) patient safety database. The government aims to expand its monitoring network, which currently includes Adverse Drug Reaction and Medical Device Monitoring Centres in various hospitals, down to the Primary Health Centre level.
Entities
Anupriya Patel · Government of India · Indian Pharmacopoeia Commission · World Health Organization